News & Updates

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022 byRoshini Claire Anthony

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
MRNA booster shot durably bolsters defenses against severe COVID-19
MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022